Fibroblast growth factor receptor 1

FGFR1
Available structures PDB Ortholog search: PDBe RCSB List of PDB id codes 1AGW, 1CVS, 1EVT, 1FGI, 1FGK, 1FQ9, 1XR0, 2CR3, 2FGI, 3C4F, 3DPK, 3GQI, 3GQL, 3JS2, 3KRJ, 3KRL, 3KXX, 3KY2, 3RHX, 3TT0, 4F63, 4F64, 4F65, 4NK9, 4NKA, 4NKS, 4RWI, 4RWJ, 4RWK, 4RWL, 4UWY, 4WUN, 5AM6, 5AM7, 4ZSA, 5A4C, 4UWB, 4UWC, 5A46, 5FLF, 5EW8, 5B7V
Identifiers
Aliases	FGFR1, BFGFR, CD331, CEK, FGFBR, FGFR-1, FLG, FLT-2, FLT2, HBGFR, HH2, HRTFDS, KAL2, N-SAM, OGD, bFGF-R-1, ECCL, fibroblast growth factor receptor 1
External IDs	OMIM: 136350 MGI: 95522 HomoloGene: 69065 GeneCards: FGFR1
Targeted by Drug
nintedanib, pazopanib, sorafenib, sunitinib[1]
Gene ontology Molecular function • kinase activity • transmembrane receptor protein tyrosine kinase activity • ATP binding • protein kinase activity • transferase activity • protein homodimerization activity • protein binding • nucleotide binding • identical protein binding • fibroblast growth factor binding • fibroblast growth factor-activated receptor activity • heparin binding • Ras guanyl-nucleotide exchange factor activity • 1-phosphatidylinositol-3-kinase activity • protein tyrosine kinase activity • phosphatidylinositol-4,5-bisphosphate 3-kinase activity Cellular component • cytoplasm • cytosol • membrane • extracellular region • nucleus • receptor complex • integral component of plasma membrane • cytoplasmic, membrane-bounded vesicle • cytoplasmic vesicle • plasma membrane • integral component of membrane Biological process • skeletal system development • ureteric bud development • fibroblast growth factor receptor signaling pathway involved in orbitofrontal cortex development • positive regulation of endothelial cell chemotaxis to fibroblast growth factor • positive regulation of MAP kinase activity • positive regulation of phospholipase C activity • regulation of branching involved in salivary gland morphogenesis by mesenchymal-epithelial signaling • positive regulation of cardiac muscle cell proliferation • mesenchymal cell differentiation • positive regulation of mesenchymal cell proliferation • angiogenesis • orbitofrontal cortex development • positive regulation of MAPKKK cascade by fibroblast growth factor receptor signaling pathway • branching involved in salivary gland morphogenesis • regulation of transcription, DNA-templated • blood vessel morphogenesis • regulation of extrinsic apoptotic signaling pathway in absence of ligand • lung development • in utero embryonic development • cell maturation • negative regulation of gene expression • transcription, DNA-templated • positive regulation of cell cycle • embryonic limb morphogenesis • positive regulation of neuron differentiation • protein autophosphorylation • auditory receptor cell development • positive regulation of MAPK cascade • paraxial mesoderm development • chondrocyte differentiation • organ induction • phosphorylation • ventricular zone neuroblast division • skeletal system morphogenesis • neuron migration • outer ear morphogenesis • negative regulation of transcription from RNA polymerase II promoter • middle ear morphogenesis • regulation of gene expression • phosphatidylinositol-mediated signaling • midbrain development • chordate embryonic development • sensory perception of sound • salivary gland morphogenesis • generation of neurons • MAPK cascade • regulation of lateral mesodermal cell fate specification • positive regulation of phospholipase activity • brain development • regulation of cell proliferation • inner ear morphogenesis • positive regulation of neuron projection development • regulation of cell differentiation • positive regulation of phosphatidylinositol 3-kinase signaling • peptidyl-tyrosine phosphorylation • lung-associated mesenchyme development • cell migration • phosphatidylinositol-3-phosphate biosynthetic process • positive regulation of GTPase activity • phosphatidylinositol phosphorylation • protein phosphorylation • fibroblast growth factor receptor signaling pathway • positive regulation of cell proliferation • regulation of phosphatidylinositol 3-kinase signaling • positive regulation of parathyroid hormone secretion • negative regulation of fibroblast growth factor production • vacuolar phosphate transport • vitamin D3 metabolic process • regulation of phosphorus metabolic process Sources:Amigo / QuickGO
RNA expression pattern
More reference expression data
Orthologs
Species	Human	Mouse
Entrez	2260	14182
Ensembl	ENSG00000077782	ENSMUSG00000031565
UniProt	P11362	P16092
RefSeq (mRNA)	NM_001174063 NM_001174064 NM_001174065 NM_001174066 NM_001174067 NM_015850 NM_023105 NM_023106 NM_023107 NM_023108 NM_023109 NM_023110 NM_023111 NM_032191	NM_001079908 NM_001079909 NM_010206
RefSeq (protein)	NP_001167534.1 NP_001167535.1 NP_001167536.1 NP_001167537.1 NP_001167538.1 NP_056934.2 NP_075593.1 NP_075594.1 NP_075598.2	NP_001073377.1 NP_001073378.1 NP_034336.2
Location (UCSC)	Chr 8: 38.41 – 38.47 Mb	Chr 8: 25.51 – 25.58 Mb
PubMed search	[2]	[3]
Wikidata

Fibroblast growth factor receptor 1 (FGFR1), also known as basic fibroblast growth factor receptor 1, fms-related tyrosine kinase-2 / Pfeiffer syndrome, and CD331, is a receptor tyrosine kinase whose ligands are specific members of the fibroblast growth factor family. FGFR1 has been shown to be associated with Pfeiffer syndrome.^[4]

Function

The protein encoded by this gene is a member of the fibroblast growth factor receptor (FGFR) family, where amino acid sequence is highly conserved between members and throughout evolution. FGFR family members differ from one another in their ligand affinities and tissue distribution. A full-length representative protein consists of an extracellular region, composed of three immunoglobulin-like domains, a single hydrophobic membrane-spanning segment and a cytoplasmic tyrosine kinase domain. The extracellular portion of the protein interacts with fibroblast growth factors, setting in motion a cascade of downstream signals, ultimately influencing mitogenesis and differentiation. This particular family member binds both acidic and basic fibroblast growth factors and is involved in limb induction.

Clinical significance

Mutations in this gene have been associated with Pfeiffer syndrome, Jackson–Weiss syndrome, Antley-Bixler syndrome, Trigonocephaly, osteoglophonic dysplasia, squamous cell lung cancer (14) and autosomal dominant Kallmann syndrome. There is also strong evidence from sequencing studies of candidate genes involved in clefting that mutations in the FGFR1 gene may be associated in the pathogenesis of cleft lip and/or palate.^[5] A few DNA sequence variants, including one nonsense mutation, have been reported in isolated or non-syndromic cleft lip and palate.^[6] Both cleft lip with or without a cleft palate and cleft palate only features have been seen in families with a FGFRI mutation.^[5] Cleft palate is a relatively common feature of Kallman syndrome as well.^[5][7][8] Somatic chromosomal aberrations involving this gene are associated with stem cell myeloproliferative disorder and stem cell leukemia lymphoma syndrome. Alternatively spliced variants which encode different protein isoforms have been described; however, not all variants have been fully characterized.^[9] Mutations in this gene have been associated to Hartsfield syndrome .^[10]

Cancer

Somatic mutations of FGFR1 occurs in several diseases including breast and lung cancers. FGFR1 has an amplification of 9%–15% in breast cancer.^[11] Its amplified expression is generally associated with poor prognosis and relapse. In ER+ breast cancer, its amplification is associated with aggressive metastasis. It is also associated as a cancer subtype as amplification of it and ERBB2 is mutually exclusive. Apart from gene amplification, a somatic mutation called K566R has also been associated with basal-like triple negative breast cancer.

Amplification of FGFR1 is also a feature in 20% of lung cancer patients. FGFR1 amplification was a single largest prognostic factor in a cohort of SCLC patients^[12] and associated with smoking. It has also been detected amplified in NSCLC cancer patients. Chromosomal translocations are an important factor in FGFR1's involvement in cancer. FN1-FGFR1 fusion is frequent in phosphaturic mesenchymal tumours.^[13][14] FGFR1 fusions have been detected with BCR and ZFN198, indicating interactions with conventional oncogenic pathways. There fusion proteins can transform cells and induce SCLL cancer in mice. Multiple myelomas also harbor a t(4;14) translocation of the FGFR1 gene. The translocation brings FGFR in proximity to the IgH enchancer region leading to overexpression. In prostate cancer, expression of FGFR1 leads to an induced EMT of cancer cells.^[15] This mechanism probably involves interaction with stromal cancer associated fibroblasts leading to dynamics that stimulates NFkB and as a result cell invasiveness.

The mechanism of FGFR1 action on cancer is largely based on abetting cancer progression and metastasis.^[16] Fibroblast growth factors trigger the autophosphorylation of the receptors at important tyrosine residues within the activation loop of the tyrosine kinase domain. This autophosphorylation results in change of the structural conformation of the tyrosine kinase domain from an inactive form to an active one ^[17] This activated tyrosine kinase domain phosphorylates tyrosine residues at other sites in FGFR1 along with FGFR1-bound adaptor molecules in a stepwise manner. This phosphorylation of the tyrosine residue at the C-terminal region of receptor allows for the binding site of phospholipase Cγ in recruiting and activating PLCγ for the catalysis and transformation of phosphatidylinositol diphosphate (PIP2) to diacylglycerol (DAG) and inositol triphosphate (IP3). FGF signals are downstream effected into the RAS-MAPK or PI3K-AKT signaling cascades.^[18] SRC tyrosine kinase are also activated by FGF signals.^[19] FGFR1 receives fibroblast binding proteins and concurrently activates both the Ras-MAPK/ERK and the PI3K pathway. Both these pathways are fundamentally important to cancer cells as they provide signals to proliferate and survive respectively. As the control of these pathways is tuned by the presence of the FGF receptor, ordinarily it would not be an issue in epithelial cells. However cancer cells that undergo EMT take up a more messenchymal state.^[20] In these cases the FGF receptors are upregulated leading to a greater tendency to move to the messenchymal state and increased aggressiveness as well as motility.

FGFR1 activity also displays focal dependence in terms of ligand signaling. Basal FGFR1 signaling was lower in FGFR1 inhibitor sensitive cell lines such as DMS114. However, on addition of FGFs, the p-ERK pathway was highly stimulated.^[21] Under steady state conditions the cell lines exhibited high levels of FGF secretion and under serum starvation conditions the cells still produced above average levels of FGF. This indicates that even under nutrition deficient conditions, FGF secretion and presence of FGFRs on cell surface allow cells to sustain growth. Interestingly, pERK could be activated by FGF1 but FGFR levels were unaffected by the presence of FGF inhibitor. This results to the conclusion that a certain baseline level of FGF activity possibly through autocrine or paracrine signaling sustains the display of FGF receptors even in conditions that normally would not favor growth. Its this counterintuitive presence of receptor that allows cancer cells to grow in a non-growth environment.^[22]

FGFR inhibitors

Recent advances in our knowledge of the FGFR1 system has resulted in attempts to discover therapeutic touch points in the pathway for use in drug development. FGFR-targeted drugs exert direct as well as indirect anticancer effects, because FGFRs on cancer cells and endothelial cells are involved in tumorigenesis and vasculogenesis, respectively.^[17] FGFR therapeutics are active as FGF affects numerous morphologies of cancers such as invasiveness, stemness and cellular survival. Primary among such drugs are antagonists. Small molecules that fit between the ATP binding pockets of the tyrosine kinase domains of the receptors. For FGFR1 numerous such small molecules are already approved for targeting of the structure of TKI ATP pocket. These include Dovitinib and Brivanib. The table below provides the IC50 (Nanomolar) of Small-Molecule Compounds Targeting FGFRs.^[17]

FGFR1 aberration in breast and lung cancer as a result of genetic overamplification is effectively targeted using Dovitinib and Povatinib respectively.^[23] Drug resistance is a highly relevant topic in the field of drug development for FGFR targets. FGFR inhibitors allow for the increase of tumor sensitivity to regular anticancer drug such as paclitaxel, and etoposide in human cancer cells and thereby enhancing antiapoptotic potential based on aberrant FGFR activation.^[17] Moreover, FGF signaling inhibition dramatically reduces revascularization, hitting upon one of the hallmarks of cancers, angiogenesis, and reduces tumor burden in human tumors that depend on autocrine FGF signaling based on FGF2 upregulation following the common VEGFR-2 therapy for breast cancer. In such a way, FGFR1 can act synergistically with therapies to cut off cancer clonal resurgence by eliminating potential pathways of future relapse.

In addition, FGFR inhibitors are predicted to be effective on relapsed tumors because of the clonal evolution of an FGFR-activated minor subpopulation after therapy targeted to EGFRs or VEGFRs. Because there are multiple mechanisms of action for FGFR inhibitors to overcome drug resistance in human cancer, FGFR-targeted therapy is a promising strategy for the treatment of refractory cancer.

AZD4547 has undergone a phase II clinical trial (re gastric cancer) and reported some results.^[24]

Lucitanib is an inhibitor of FGFR1 and FGFR2 and has undergone clinical trials for advanced solid tumors.^[25]

Dovitinib (TKI258), an inhibitor of FGFR1, FGFR2, and FGFR3, has had a clinical trial on FGFR-amplified breast cancers.^[26]

Interaction with PLCγ

Figure 1. SH2 domains in complex with FGFR1 kinase. c-SH2 domain is colored in blue, n-SH2 domain is colored in red, and the interdomain linker is colored in yellow. FGFR1 kinase (green) interacts with n-SH2 domain at its C-terminal tail. The structure contains typical SH2 domain, with two α-helices and three antiparallel β-strands on each of the SH2 domains.

Receptor tyrosine kinase (RTK) signaling plays an important role in various signaling pathways in human biology. The phosphorylation of tyrosines at the juxtamembrane region, kinase insert, or C-terminal tail of RTKs creates a docking site for the binding of Src Homology 2 (SH2) domain in RTK signaling pathways. SH2 domain recognizes the phosphorylated tyrosine residues (pTyr) on its substrate to activate a specific intracellular signaling pathway. Previous studies have also shown that RTKs utilize their unique autophosphorylation properties to recruit target proteins upon ligand stimulation.

The phosphorylation of a highly conserved tyrosine residue (Y766) at the C-terminal tail of Fibroblast growth factor 1 (FGFR1) creates a binding site to recruit Phospholipase C gamma (PLCγ), a tandem nSH2- cSH2 containing domain, to facilitate phosphorylation of PLCγ. Phosphorylated PLCγ relieves its autoinhibition, facilitates the enzymatic activity to hydrolyze phosphatidylinositol 4,5-bisphosphate (PIP2) to inositol 1,4,5-trisphosphate (IP3) and second messenger diacyglycerol (DAG). These molecules then serves as a second messenger for other signaling pathways.

Recent publication on the 2.5 Å crystal structure of PLCγ in complex with FGFR1 kinase (PDB: 3GQI) provides new insights in understanding the molecular mechanism of substrate recruitment by SH2 domain to its substrate. Figure 1 shows the PLCγ-FGFR1 kinase complex with the c-SH2 domain colored in red, n-SH2 domain colored in blue, and the interdomain linker is colored in yellow. The structure contains typical SH2 domain, with two α-helices and three antiparallel β-strands on each SH2 domain. In this complex, the phosphorylated tyrosine (pY766) on the C-terminal tail of FGFR1 kinase binds preferentially to the nSH2 domain of PLCγ. The phosphorylation of tyrosine residue 766 on FGFR1 kinase forms hydrogen bonds with the n-SH2 to stabilize the complex. Hydrogen bonds in the binding pocket help to stabilize the PLCγ-FGFR1 kinase complex. The water molecule as shown mediates the interaction of asparagine 647 (N647) and aspartate 768 (D768) to further increase the binding affinity of the n-SH2 and FGFR1 kinase complex. (Figure 2).

The phosphorylation of tyrosine 653 and tyrosine 654 in the active kinase conformation causes a large conformation change in the activation segment of FGFR1 kinase. Threonine 658 is moved by 24Å from the inactive form (Figure 3.) to the activated form of FGFR1 kinase (Figure 4.). The movement causes the closed conformation in the inactive form to open to enable substrate binding. It also allows the open conformation to coordinate Mg2+ with AMP-PCP (analog of ATP). In addition, pY653 and pY654 in the active form helps to maintain the open conformation of the SH2 and FGFR1 kinase complex. However, the mechanism of which the phosphorylation at Y653 and Y654 helps to recruit SH2 domain to its C-terminal tail upon phosphorylation of Y766 remains elusive. Figure 5 shows the overlay structure of active and inactive forms of FGFR1 kinase. Figure 6 shows the dots and contacts on phosphorylated tyrosine residues 653 and 654. Green dots show highly favorable contacts between pY653 and pY654 with surrounding residues. Red spikes show unfavorable contacts in the activation segment. The figure is generated through Molprobity extension on Pymol.

• 
  Figure 2. Hydrogen bonds at pY766
• 
  Figure 3. Closed conformation in Inactive FRFR1 kinase
• 
  Figure 4. Open conformation in active FRFR1 kinase
• 
  Figure 5. Overlay Structures of Active and Inactive Forms of FGFR1 kinase
• 
  Figure 6. Dots and contacts on pY653 & pY654
• 
  Figure 7. The β-factor of the PLC-FGFR1 kinase complex

N-SH2 binding site interface

Figure 8. Interface on the N-SH2 binding site and FGFR1 kinase. The FGFR1 kinase is bound to the N-SH2 domain primarily through charged amino acids. The acid base pair (D755 and R609) located in the middle of the interface are nearly parallel to each other, indicating a highly favorable interaction.

The FGFR1 kinase is bound to the N-SH2 domain primarily through charged amino acids. Arginine residue (R609) on the N-SH2 domain forms a salt bridge to aspartate 755 (D755) on the FGFR1 domain. The acid base pair located in the middle of the interface are nearly parallel to each other, indicating a highly favorable interaction. N-SH2 domain makes an additional polar contact through water-mediated interaction that takes place between the N-SH2 domain and FGFR1 kinase. Interestingly, the arginine residue 609 (R609) on the FGFR1 kinase also forms a salt bridge to the aspartate residue (D594) on the N-SH2 domain. The acid-base pair interacts with each other carry out redox reaction to stabilize the complex (Figure 7). Previous studies have done to elucidate the binding affinity of the n-SH2 domain with the FGFR1 kinase complex by mutating these amino acids phenyalanine or valine. The results from isothermal titration calorimetry (ITC) indicated that the binding affinity of the complex decreased by 3 to 6-fold, without affecting the phosphorylation of the tyrosine residues. ^[27]

Interactions

Fibroblast growth factor receptor 1 has been shown to interact with:

• FGF1,^[28][29]
• FRS2,^{[30][31][32][33]}
• Klotho,^[34]
• GRB14,^[35] and
• SHB.^[36]

See also

• Cluster of differentiation

References

Further reading

External links

• GeneReviews/NIH/NCBI/UW entry on FGFR-Related Craniosynostosis Syndromes
• GeneReviews/NCBI/NIH/UW entry on Kallmann syndrome
• FGFR1 protein, human at the US National Library of Medicine Medical Subject Headings (MeSH)
• Fibroblast growth factor receptor 1 on the Atlas of Genetics and Oncology
• FGFR1 human gene location in the UCSC Genome Browser.
• FGFR1 human gene details in the UCSC Genome Browser.

This article incorporates text from the United States National Library of Medicine, which is in the public domain.

PDB gallery
1agw: CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU4984 INHIBITOR  1cvs: CRYSTAL STRUCTURE OF A DIMERIC FGF2-FGFR1 COMPLEX  1evt: CRYSTAL STRUCTURE OF FGF1 IN COMPLEX WITH THE EXTRACELLULAR LIGAND BINDING DOMAIN OF FGF RECEPTOR 1 (FGFR1)  1fgi: CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1 IN COMPLEX WITH SU5402 INHIBITOR  1fgk: CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FIBROBLAST GROWTH FACTOR RECEPTOR 1  1fq9: CRYSTAL STRUCTURE OF A TERNARY FGF2-FGFR1-HEPARIN COMPLEX  2ckn: NMR STRUCTURE OF THE FIRST IG MODULE OF MOUSE FGFR1  2cr3: Solution structure of the first Ig-like domain of human fibroblast growth factor receptor 1  2fgi: CRYSTAL STRUCTURE OF THE TYROSINE KINASE DOMAIN OF FGF RECEPTOR 1 IN COMPLEX WITH INHIBITOR PD173074